Gemifloxacin for the treatment of community-acquired pneumonia and acute exacerbation of chronic bronchitis: A meta-analysis of randomized controlled trials

Chinese Medical Journal

Volumn 125, Issue 4, 2012, Pages 687-695

  Zhang, Lei ^a   Wang, Rui ^a   Matthew, Falagas E ^b   Chen, Liang An ^a   Liu, You Ning ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b ALFA INSTITUTE OF BIOMEDICAL SCIENCES AIBS   (Greece)

Author keywords

Beta lactams; Gemifloxacin; Quinolones; Safety

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; BETA LACTAM ANTIBIOTIC; CEFTRIAXONE; CEFUROXIME; CLARITHROMYCIN; GEMIFLOXACIN; LEVOFLOXACIN; MACROLIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TROVAFLOXACIN;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; CHRONIC BRONCHITIS; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED STUDY; DATA ANALYSIS; DIARRHEA; DISEASE EXACERBATION; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG SENSITIVITY; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; MORTALITY; NAUSEA; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; SYSTEMATIC REVIEW;

ANTI-BACTERIAL AGENTS; BRONCHITIS, CHRONIC; COMMUNITY-ACQUIRED INFECTIONS; FLUOROQUINOLONES; HUMANS; NAPHTHYRIDINES; PNEUMONIA; QUINOLONES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84863118235     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2012.04.024     Document Type: Article

References (54)

1. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44 Suppl 2: s27-s72.
2. Tillotson GS. Role of gemifloxacin in community-acquired pneumonia. Expert Rev Anti Infect Ther 2008; 6: 40 5-418.
3. Lopez AD, Shibuya K, Rao C, Mathers CD, Hansell AL, Held LS, et al. Chronic obstructive pulmonary disease: current burden and future projections. Eur Respir J 2006; 27: 39 7-412.
4. Bellamy D, Bouchard J, Henrichsen S, Johansson G, Langhammer A, Reid J, et al. International Primary Care Respiratory Group (IPCRG) Guidelines: management of chronic obstructive pulmonary disease (COPD). Prim Care Respir J 2006; 15: 4 8-57.
5. Shams WE, Evans ME. Guide to selection of fluoroquinolones in patients with lower respiratory tract infections. Drugs 2005; 65: 94 9-991.
6. Felmingham D, Shackcloth J, Tillotson G. BSAC Respiratory Resistance Surveillance Programme (2002-2003): comparative susceptibility of Streptococcus pneumoniae, cultured from patients in Great Britain and Ireland with community-acquired lower respiratory tract infection, to gemifloxacin. J Antimicrob Chemother 2004; 54: 69 8-699.
7. Liu YN, Zhao TM, Yao WZ, Zhang LS, He ZY, Jiao YM, et al. Prevalence of atypical pathogens in adult patients with community-acquired pneumonia in Beijing. Chin J Tuberc Respir Dis (Chin) 2004; 27: 2 7-30.
8. Blondeau JM, Vaughan D, Laskowski R, Borsos S. Susceptibility of Canadian isolates of Haemophilus influenzae, Moraxella catarrhalis and Streptococcus pneumoniae to oral antimicrobial agents. Int J Antimicrob Agents 2001; 17: 45 7-464.
9. Nazir J, Urban C, Mariano N, Burns J, Tommasulo B, Rosenberg C, et al. Quinolone-resistant Haemophilus influenzae in a long-term care facility: clinical and molecular epidemiology. Clin Infect Dis 2004; 38: 156 4-1569.
10. Jindal SK, Gupta D, Aggarwal AN. Guidelines for management of chronic obstructive pulmonary disease (COPD) in India: a guide for physicians (2003). Indian J Chest Dis Allied Sci 2004; 46: 13 7-153.
11. Russi EW, Leuenberger P, Brandli O, Frey JG, Grebski E, Gugger M, et al. Management of chronic obstructive pulmonary disease: the Swiss guidelines. Official Guidelines of the Swiss Respiratory Society. Swiss Med Wkly 2002; 132: 6 7-78.
12. Pierson DJ. New international guidelines for chronic obstructive pulmonary disease. Respir Care 2001; 46: 76 8-771.
13. Laitinen LA, Koskela K. Chronic bronchitis and chronic obstructive pulmonary disease: Finnish National Guidelines for Prevention and Treatment 199 8-2007. Respir Med 1999; 93: 29 7-332.
14. Roig J, Casal J, Gispert P, Gea E. 13--Antibiotic therapy of community-acquired pneumonia (CAP) caused by atypical agents. Med Mal Infect 2006; 36: 680-689.
15. Peuchant O, Menard A, Renaudin H, Morozumi M, Ubukata K, Bebear CM, et al. Increased macrolide resistance of Mycoplasma pneumoniae in France directly detected in clinical specimens by real-time PCR and melting curve analysis. J Antimicrob Chemother 2009; 64: 5 2-58.
16. Liu Y, Ye X, Zhang H, Xu X, Li W, Zhu D, et al. Antimicrobial susceptibility of Mycoplasma pneumoniae isolates and molecular analysis of macrolide-resistant strains from Shanghai, China. Antimicrob Agents Chemother 2009; 53: 216 0-2162.
17. Okazaki N, Ohya H, Sasaki T. Mycoplasma pneumoniae isolated from patients with respiratory infection in Kanagawa Prefecture in 1976-2006: emergence of macrolide-resistant strains. Jpn J Infect Dis 2007; 60: 32 5-326.
18. Li X, Atkinson TP, Hagood J, Makris C, Duffy LB, Waites KB. Emerging macrolide resistance in Mycoplasma pneumoniae in children: detection and characterization of resistant isolates. Pediatr Infect Dis J 2009; 28: 69 3-696.
19. Kolditz M, Halank M, Hoffken G. Monotherapy versus combination therapy in patients hospitalized with community-acquired pneumonia. Treat Respir Med 2006; 5: 37 1-383.
20. Balter M, Weiss K. Treating acute exacerbations of chronic bronchitis and community-acquired pneumonia: how effective are respiratory fluoroquinolones? Can Fam Physician 2006; 52: 123 6-1242.
21. Doern GV, Richter SS, Miller A, Miller N, Rice C, Heilmann K, et al. Antimicrobial resistance among Streptococcus pneumoniae in the United States: have we begun to turn the corner on resistance to certain antimicrobial classes? Clin Infect Dis 2005; 41: 13 9-148.
22. Defres S, Marwick C, Nathwani D. MRSA as a cause of lung infection including airway infection, community-acquired pneumonia and hospital-acquired pneumonia. Eur Respir J 2009; 34: 147 0-1476.
23. Morrissey I, Ge Y, Janes R. Activity of the new cephalosporin ceftaroline against bacteraemia isolates from patients with community-acquired pneumonia. Int J Antimicrob Agents 2009; 33: 51 5-519.
24. Xue XY, Gao ZC, Zhu JH, Xu Y, Li X. Clinical evaluation of chinese guidelines for community-acquired pneumonia. J Peking Univ (Health Sci) (Chin) 2006; 38: 27 6-279.
25. Jivcu C, Gotfried M. Gemifloxacin use in the treatment of acute bacterial exacerbation of chronic bronchitis. Int J Chron Obstruct Pulmon Dis 2009; 4: 29 1-300.
26. Lode HM, Schmidt-Ionas M, Stahlmann R. Gemifloxacin for community-acquired pneumonia. Expert Opin Investig Drugs 2008; 17: 77 9-786.
27. Blondeau JM, Tillotson G, Deangelis J. Geminofloxacin for the management of community-acquired respiratory tract infections. J Chemother 2006; 18: 58 2-588.
28. Bhavnani SM, Andes DR. Gemifloxacin for the treatment of respiratory tract infections: in vitro susceptibility, pharmacokinetics and pharmacodynamics, clinical efficacy, and safety. Pharmacotherapy 2005; 25: 71 7-740.
29. Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet 1998; 352: 60 9-613.
30. Vardakas KZ, Siempos, II, Grammatikos A, Athanassa Z, Korbila IP, Falagas ME. Respiratory fluoroquinolones for the treatment of community-acquired pneumonia: a meta-analysis of randomized controlled trials. CMAJ 2008; 179: 126 9-1277.
31. Siempos II, Dimopoulos G, Korbila IP, Manta K, Falagas ME. Macrolides, quinolones and amoxicillin/clavulanate for chronic bronchitis: a meta-analysis. Eur Respir J 2007; 29: 112 7-1137.
32. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 62 9-634.
33. Hammerschlag MR. Efficacy and safety of gemifloxacin in the treatment of community-acquired pneumonia: a randomized, double-blind comparison with trovafloxacin. J Antimicrob Chemother 2001; 48: 735.
34. Niederman M, Wilson R, Seltzer E. Short course (5 day) Gemifloxacin therapy is as at least as effective as 7 day Levofloxavin in the treatment of acute exacerbations of chronic bronchitis. Am J Respir Crit Care Med 2002; 165 Suppl: s279.
35. Santos J, Aguilar L, Garcia-Mendez E, Siquier B, Custardoy J, Garcia-Rey C, et al. Clinical characteristics and response to newer quinolones in Legionella pneumonia: a report of 28 cases. J Chemother 2003; 15: 46 1-465.
36. Glenn S, Tillotson, Fulambarker A. 5 Days oral gemifloxacin compared to 7 days oral levofloxacin in the treatment of acute exacerbation of chronic bronchitis. Chest 2004; 126 Suppl: s839.
37. Wilson R, Ball P, Pypstra R. Oral gemifloxacin vs. sequential I.V. ceftriaxone followed by oral cefuoxime in the treatment of hospitalized patients with acute exacerbations of chronic bronchitis. Am J Respir Crit Care Med 2002; 165 Suppl: s270.
38. Spencer S. Gemifloxacin produces greater improvement in health status of smokers and ex-smokers treated for acute exacerbations of chronic bronchitis compared to clarithromycin. Am J Respir Crit Care Med 2001; 163 Suppl: s507.
39. Spencer S, Jones PW. Time course of recovery of health status following an infective exacerbation of chronic bronchitis. Thorax 2003; 58: 58 9-593.
40. Vousden M, Ferguson J, Richards J, Bird N, Allen A. Evaluation of phototoxic potential of gemifloxacin in healthy volunteers compared with ciprofloxacin. Chemotherapy 1999; 45: 51 2-520.
41. Ball P, Wilson R, Mandell L, Brown J, Henkel T. Efficacy of gemifloxacin in acute exacerbations of chronic bronchitis: a randomised, double-blind comparison with trovafloxacin. J Chemother 2001; 13: 28 8-298.
42. File T, Schlemmer B, Garau J, Lode H, Lynch S, Young C. Gemifloxacin versus amoxicillin/clavulanate in the treatment of acute exacerbations of chronic bronchitis. The 070 Clinical Study group. J Chemother 2000; 12: 31 4-325.
43. File TM Jr, Schlemmer B, Garau J, Cupo M, Young C. Efficacy and safety of gemifloxacin in the treatment of community-acquired pneumonia: a randomized, double-blind comparison with trovafloxacin. J Antimicrob Chemother 2001; 48: 6 7-74.
44. Leophonte P, File T, Feldman C. Gemifloxacin once daily for 7 days compared to amoxicillin/clavulanic acid thrice daily for 10 days for the treatment of community-acquired pneumonia of suspected pneumococcal origin. Respir Med 2004; 98: 70 8-720.
45. Lode H, File TM Jr, Mandell L, Ball P, Pypstra R, Thomas M. Oral gemifloxacin versus sequential therapy with intravenous ceftriaxone/oral cefuroxime with or without a macrolide in the treatment of patients hospitalized with community-acquired pneumonia: a randomized, open-label, multicenter study of clinical efficacy and tolerability. Clin Ther 2002; 24: 191 5-1936.
46. Sethi S, Fogarty C, Fulambarker A. A randomized, double-blind study comparing 5 days oral gemifloxacin with 7 days oral levofloxacin in patients with acute exacerbation of chronic bronchitis. Respir Med 2004; 98: 69 7-707.
47. Shi HY, Huang ZY, Huang YH, Fan Y, Shen MQ, Qiu YQ. Gemifloxacin versus levofloxacin in treatment of lower respiratory tract infection: a randomized controlled trial. Chin J New Drugs Clin Rem (Chin) 2007; 26: 67 8-680.
48. Wilson R, Langan C, Ball P, Bateman K, Pypstra R. Oral gemifloxacin once daily for 5 days compared with sequential therapy with i.v. ceftriaxone/oral cefuroxime (maximum of 10 days) in the treatment of hospitalized patients with acute exacerbations of chronic bronchitis. Respir Med 2003; 97: 24 2-249.
49. Wilson R, Schentag JJ, Ball P, Mandell L. A comparison of gemifloxacin and clarithromycin in acute exacerbations of chronic bronchitis and long-term clinical outcomes. Clin Ther 2002; 24: 63 9-652.
50. Yao ZP. A study of the effectiveness of gemifloxacin on chronic obstructive pulmonary disease. Pract Clin Med 2008; 9: 3 6-37.
51. Jacobs MR, Felmingham D, Appelbaum PC, Gruneberg RN. The Alexander Project 1998-2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents. J Antimicrob Chemother 2003; 52: 22 9-246.
52. Ball P. Quinolone generations: natural history or natural selection? J Antimicrobial Chemotherapy 2000; 46: 1 7-24.
53. Appelbaum PC, Hunter PA. The fluoroquinolone antibacterials: past, present and future perspectives. Int J Antimicrob Agents 2000; 16: 5-15.
54. Zhanel GG, Ennis K, Vercaigne L, Walkty A, Gin AS, Embil J, et al. A critical review of the fluoroquinolones: focus on respiratory infections. Drugs 2002; 62: 1 3-59.